

Australia Lung Cancer Screening Market Forecast to 2030 - COVID-19 Impact and Country Analysis by Cancer Type [Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer], Technology [Low-Dose Computed Tomography (LDCT), Chest X-Ray, Liquid Biopsy, and Others], Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

Market Report | 2023-07-04 | 127 pages | The Insight Partners

AVAILABLE LICENSES:

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

Report description:

The Australia lung cancer screening market size is expected to grow from US\$ 2.74 million in 2022 to US\$ 6.12 million by 2030; it is estimated to record a CAGR of 10.6% from 2022 to 2030.

The Australia lung cancer screening market growth is attributed to the increasing Incidence of lung cancer and rising government support. However, uncertainties related to lung cancer screening trial with LDCT is hampering the growth of the Australia lung cancer screening market.

Lung cancer screening is a process used to detect lung cancer in otherwise healthy people with a high risk of lung cancer. Lung cancer screening is recommended for older adults who are long time smokers and who don't have any signs or symptoms of lung cancer. Doctors use a LDCT scan of the lungs to look for lung cancer. If lung cancer is detected early, it's more likely to be cured with treatment.

Structured Lung Cancer Screening Program is expected to provide the opportunities in the forecast period.

Australia faces unique challenges with lung cancer screening programs. A few examples of population-based Australian screening programs are "BreastScreen," the "National Bowel Cancer Screening Program," and the "National Cervical Screening Program."

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Therefore, there is a crucial requirement for a well-structured program such as a community-based program or a shared, informed decision-making program between clinicians and potential participants; accredited reporting centers; and a central data registry for quality control, monitoring, and outcome reporting. Additionally, integrated smoking cessation intervention, international data supporting cost-effectiveness, additional mortality benefits, and a high sustainability rate are a few factors that must be studied for lung cancer screening. Further, the International Association for the Study of Lung Cancer (IASLC) recommends implementing feasibility screening programs in the country without participating in lung cancer screening studies. These programs involve smoking cessation initiatives, standardized algorithms for selecting and managing screening participants, and specialist multidisciplinary teams to manage participants with positive screening results. Therefore, the implementation of structured lung cancer screening programs in the country is expected to be a lucrative opportunity in the Australia lung cancer screening market during the forecast period.

Australia Lung Cancer Screening Market - Test Type Insights

Based on cancer type, the Australia lung cancer screening market is bifurcated into NSCLC and small cell lung cancer. The NSCLC segment accounted for the largest market share in 2022 and is expected to grow at a CAGR of 10.3% during the forecast period. The market position of this segment is due to the rising cases of NSCLC in Australia. NSCLC develops more slowly than small cell lung cancer. It usually spreads to other parts of the patient's body by the time it is diagnosed. Therefore, early diagnosis and treatment are crucial. According to National Foundation for Cancer Research, NSCLC accounts for nearly 9 out of every 10 diagnoses. As per the same source, large-cell undifferentiated carcinoma lung cancer accounts for approximately 10-15% of all NSCLC diagnoses.

Based on technology, the Australia lung cancer screening market is segmented into LDCT, chest X-ray, liquid biopsy, and others. The chest X-ray segment accounted for the largest market share in 2022, however, the LDCT is expected to grow at a CAGR of 11.9% during the forecast period.

Based on age group, the Australia lung cancer screening market is bifurcated into 50 & older and below 50. The 50 & older segment accounted for the largest market share in 2022, however, the below 50 is expected to grow at a CAGR of 11.3% during the forecast period.

Based on end user, the Australia lung cancer screening market is segmented into hospitals, diagnostic centers, and others. The hospitals segment accounted for the largest market share in 2022, however, the others is expected to grow at a CAGR of 11.1% during the forecast period.

Australia Lung Cancer Screening Market - Recent Developments:

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the Australia lung cancer screening market. A few recent key market developments are listed below:

In June 2022, Royal Philips teamed up with Biodesix, Inc. to incorporate the results of Biodesix's Nodify Lung blood-based lung nodule risk assessment testing into Philips Lung Cancer Orchestrator lung cancer patient management system. The incorporation of proteomics data along with the radiologic and patient history data currently used to determine treatment decisions can help create diagnostic efficiency for cancer care centers in the management of a growing number of lung nodule cases via the contextual launch of Biodesix Nodify Lung application within Lung Cancer Orchestrator.

In August 2022, Intelrad Medical Systems acquired PenRad Technologies, Inc., a software provider for enhancing breast imaging and lung screening productivity. The acquisition has expanded Intelrad's product offerings for mammography and lung analytics, optimizing workflow for radiologists and boosting patient health outcomes.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Table of Contents:

TABLE OF CONTENTS

- 1. Introduction
 - 1.1 Scope of the Study
 - 1.2 The Insight Partners Research Report Guidance
 - 1.3 Market Segmentation
 - 1.3.1 Australia Lung Cancer Screening Market - by Technology
 - 1.3.2 Australia Lung Cancer Screening Market - by Cancer Type
 - 1.3.3 Australia Lung Cancer Screening Market - by Age Group
 - 1.3.4 Australia Lung Cancer Screening Market - by End User
- 2. Australia Lung Cancer Screening Market - Key Takeaways
- 3. Research Methodology
 - 3.1 Coverage
 - 3.2 Secondary Research
 - 3.3 Primary Research
- 4. Australia Lung Cancer Screening Market - Market Landscape
 - 4.1 Overview
 - 4.2 PEST Analysis
 - 4.3 Expert's Opinion
 - 4.4 Demographics of Smoking, by Key States
 - 4.5 Demographics of Smoking, by Income Bracket
 - 4.6 Epidemiology of Lung Cancer in Australia
 - 4.7 Patterns of Smoking in Australia
 - 4.8 Trends Of Smoking in Australia
 - 4.9 Regional Comparative Analysis of Smoking (Asian and European)
- 5. Market Dynamics
 - 5.1 Market Drivers
 - 5.1.1 Increasing Incidence of Lung Cancer
 - 5.1.2 Rising Government Support
 - 5.2 Market Restraints
 - 5.2.1 Uncertainties Related to Lung Cancer Screening Trial with LDCT
 - 5.3 Market Opportunities
 - 5.3.1 Structured Lung Cancer Screening Program
 - 5.4 Future Trends
 - 5.4.1 Mobile Lung Cancer Screening Truck
 - 5.5 Impact Analysis
- 6. Lung Cancer Screening Market - Australia Analysis
 - 6.1 Australia Lung Cancer Screening Market Revenue Forecast and Analysis
- 7. Australia Lung Cancer Screening Market Analysis - by Cancer Type
 - 7.1 Overview
 - 7.2 Australia Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 2030 (US\$ Thousand)
 - 7.3 Non-Small Cell Lung Cancer (NSCLC)
 - 7.3.1 Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.2 Non-small cell lung cancer (NSCLC): Australia Lung Cancer Screening Market - Revenue and Forecast to 2030 (US\$ Thousand)
- 7.4 Small Cell Lung Cancer
 - 7.4.1 Overview
 - 7.4.2 Small Cell Lung Cancer: Australia Lung Cancer Screening Market - Revenue and Forecast to 2030 (US\$ Thousand)
- 8. Australia Lung Cancer Screening Market Analysis - by Technology
 - 8.1 Overview
 - 8.2 Australia Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US\$ Thousand)
 - 8.3 Low-Dose Computed Tomography (LDCT)
 - 8.3.1 Overview
 - 8.3.2 Low-Dose Computed Tomography (LDCT): Lung Cancer Screening Market- Revenue and Forecast to 2030 (US\$ Thousand)
 - 8.4 Chest X-ray
 - 8.4.1 Overview
 - 8.4.2 Chest X-ray: Lung Cancer Screening Market- Revenue and Forecast to 2030 (US\$ Thousand)
 - 8.5 Liquid Biopsy
 - 8.5.1 Overview
 - 8.5.2 Liquid Biopsy: Lung Cancer Screening Market- Revenue and Forecast to 2030 (US\$ Thousand)
 - 8.6 Others
 - 8.6.1 Overview
 - 8.6.2 Others: Lung Cancer Screening Market- Revenue and Forecast to 2030 (US\$ Thousand)
- 9. Australia Lung Cancer Screening Market Analysis - by Age Group
 - 9.1 Overview
 - 9.2 Australia Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US\$ Thousand)
 - 9.3 & Older
 - 9.3.1 Overview
 - 9.3.2 & Older: Australia Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US\$ Thousand)
 - 9.4 Below 50
 - 9.4.1 Overview
 - 9.4.2 Below 50: Australia Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US\$ Thousand)
- 10. Australia Lung Cancer Screening Market Analysis - by End User
 - 10.1 Overview
 - 10.2 Australia Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US\$ Thousand)
 - 10.3 Hospitals
 - 10.3.1 Overview
 - 10.3.2 Hospitals: Australia Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US\$ Thousand)
 - 10.4 Diagnostic Centers
 - 10.4.1 Overview
 - 10.4.2 Diagnostic Centers: Australia Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US\$ Thousand)
 - 10.5 Others
 - 10.5.1 Overview
 - 10.5.2 Others: Australia Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US\$ Thousand)
- 11. Australia Lung Cancer Screening Market: Impact Assessment of COVID-19 Pandemic
 - 11.1 Impact Analysis of COVID-19 Pandemic on Australia Lung Cancer Screening Market
- 12. Australia Lung Cancer Screening Market-Industry Landscape
 - 12.1 Recent Growth Strategies
 - 12.1.1 Overview
- 13. Company Profiles

- 13.1 Intelrad Medical Systems
 - 13.1.1 Key Facts
 - 13.1.2 Business Description
 - 13.1.3 Products and Services
 - 13.1.4 Financial Overview
 - 13.1.5 SWOT Analysis
 - 13.1.6 Key Developments
- 13.2 Nuance Communications Inc
 - 13.2.1 Key Facts
 - 13.2.2 Business Description
 - 13.2.3 Products and Services
 - 13.2.4 Financial Overview
 - 13.2.5 SWOT Analysis
 - 13.2.6 Key Developments
- 13.3 GE HealthCare
 - 13.3.1 Key Facts
 - 13.3.2 Business Description
 - 13.3.3 Products and Services
 - 13.3.4 Financial Overview
 - 13.3.5 SWOT Analysis
 - 13.3.6 Key Developments
- 13.4 Medtronic
 - 13.4.1 Key Facts
 - 13.4.2 Business Description
 - 13.4.3 Products and Services
 - 13.4.4 Financial Overview
 - 13.4.5 SWOT Analysis
 - 13.4.6 Key Developments
- 13.5 Canon Inc.
 - 13.5.1 Key Facts
 - 13.5.2 Business Description
 - 13.5.3 Products and Services
 - 13.5.4 Financial Overview
 - 13.5.5 SWOT Analysis
 - 13.5.6 Key Developments
- 13.6 Koninklijke Philips NV
 - 13.6.1 Key Facts
 - 13.6.2 Business Description
 - 13.6.3 Products and Services
 - 13.6.4 Financial Overview
 - 13.6.5 SWOT Analysis
 - 13.6.6 Key Developments
- 13.7 Siemens AG
 - 13.7.1 Key Facts
 - 13.7.2 Business Description
 - 13.7.3 Products and Services
 - 13.7.4 Financial Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 CVS Health
 - 13.8.1 Key Facts
 - 13.8.2 Business Description
 - 13.8.3 Products and Services
 - 13.8.4 Financial Overview
 - 13.8.5 SWOT Analysis
 - 13.8.6 Key Developments
- 13.9 bioAffinity Technologies, Inc.
 - 13.9.1 Key Facts
 - 13.9.2 Business Description
 - 13.9.3 Products and Services
 - 13.9.4 Financial Overview
 - 13.9.5 SWOT Analysis
 - 13.9.6 Key Developments
- 13.10 LungLife AI, Inc.
 - 13.10.1 Key Facts
 - 13.10.2 Business Description
 - 13.10.3 Products and Services
 - 13.10.4 Financial Overview
 - 13.10.5 SWOT Analysis
 - 13.10.6 Key Developments
- 13.11 Lung Screen Australia Pty Ltd
 - 13.11.1 Key Facts
 - 13.11.2 Business Description
 - 13.11.3 Products and Services
 - 13.11.4 Financial Overview
 - 13.11.5 SWOT Analysis
 - 13.11.6 Key Developments
- 14. Appendix
 - 14.1 About The Insight Partners
 - 14.2 Glossary of Terms

Australia Lung Cancer Screening Market Forecast to 2030 - COVID-19 Impact and Country Analysis by Cancer Type [Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer], Technology [Low-Dose Computed Tomography (LDCT), Chest X-Ray, Liquid Biopsy, and Others], Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

Market Report | 2023-07-04 | 127 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-20"/>
		Signature	<input type="text"/>